ATYR

USD

aTyr Pharma Inc. Common Stock

$5.395-0.155 (-2.793%)

السعر في الوقت الحقيقي

Healthcare

التكنولوجيا الحيوية

الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق

أساسيات الشركة

إحصاءات التداول

مقاييس السوق

الافتتاح

$5.550

الأعلى

$5.749

الأدنى

$5.330

الحجم

2.00M

أساسيات الشركة

القيمة السوقية

480.2M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

1.63M

البورصة

NCM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $1.42الحالي $5.395الأعلى $5.98

أخبار ذات صلة

٤ يونيو ٢٠٢٥ · ٠٣:٤٥ م

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.

عرض المزيد

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

٤ يونيو ٢٠٢٥ · ١٢:٠٠ م

GlobeNewswire

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well

عرض المزيد

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

١٩ مايو ٢٠٢٥ · ١٢:٠٠ م

GlobeNewswire

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world

عرض المزيد

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

١٩ مايو ٢٠٢٥ · ١١:١٠ ص

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.

عرض المزيد

١٦ مايو ٢٠٢٥ · ٠٨:٠١ م

GlobeNewswire

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from

عرض المزيد